Adenovirus-mediated TA-p73β gene transfer increases chemosensitivity of human malignant melanomas

Apoptosis

Volumn 11, Issue 2, 2006, Pages 235-243

  Tuve, S ^a   Racek, T ^a   Niemetz, A ^a   Schultz, J ^a   Soengas, M S ^b   Putzer B M ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Apoptosis; Chemotherapy; Gene therapy; Melanoma; p73

Indexed keywords

CISPLATIN; DOXORUBICIN; PROTEIN P73;

ADENOVIRUS; ADENOVIRUS VECTOR; ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL FUNCTION; CHEMOSENSITIVITY; CONTROLLED STUDY; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SEQUENCE HOMOLOGY; XENOGRAFT;

ADENOVIRIDAE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG SYNERGISM; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, TUMOR SUPPRESSOR; HUMANS; MELANOMA; MICE; MICE, NUDE; NUCLEAR PROTEINS; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; ANIMALIA;

EID: 33344459643     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10495-006-3407-0     Document Type: Article

References (31)

1. Bajetta E, Del Vecchio M, Bernard-Marty C, et al. Metastatic melanoma: chemotherapy. Semin Oncol. 2002; 29: 427-445.
2. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003; 22: 3138-3151.
3. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J. Invest. Dermatol. 1999; 113: 1076-1081.
4. Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001; 409: 207-211.
5. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
6. Lubbe J, Reichel M, Burg G, Kleihues P. Absence of p53 gene mutations in cutaneous melanoma. J. Invest. Dermatol. 1994; 102: 819-821.
7. Chin L, Pomerantz J, Polsky D, et al. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes. Dev. 1997; 11: 2822-2834.
8. Stiewe T, Putzer BM. Role of p73 in malignancy: tumor suppressor or oncogene? Cell Death Differ. 2002; 9: 237-245.
9. Gong JG, Costanzo A, Yang HQ, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999; 399: 806-809.
10. Yuan ZM, Shioya H, Ishiko T, et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 1999; 399: 814-817.
11. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG Jr. Chemosensitivity linked to p73 function. Cancer Cell 2003; 3: 403-410.
12. Chen X, Zheng Y, Zhu J, Jiang J, Wang J. p73 is transcriptionally regulated by DNA damage, p53, and p73. Oncogene 2001; 20: 769-774.
13. Bergamaschi D, Gasco M, Hiller L, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent aoptosis. Cancer Cell 2003; 3: 387-402.
14. Stiewe T, Zimmermann S, Frilling A, Esche H, Putzer BM. Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res. 2002; 62: 3598-3602.
15. Zaika AI, Slade N, Erster SH, et al. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J. Exp. Med. 2002; 196: 765-780.
16. Vossio S, Palescandolo E, Pediconi N, et al. DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. Oncogene 2002; 21: 3796-3803.
17. Zhang H, Schneider J, Rosdahl I. Expression of p16, p27, p53, p73 and Nup88 proteins in matched primary and metastatic melanoma cells. Int. J. Oncol. 2002; 21: 43-48.
18. Tuve S, Wagner SN, Schittek B, Putzer BM. Alterations of DeltaTA-p73 splice transcripts during melanoma development and progression. Int. J. Cancer 2004; 108: 162-166.
19. Stiewe T, Theseling CC, Putzer BM. Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J. Biol. Chem. 2002; 277: 14177-14185.
20. Rödicker F, Pützer BM. p73 is effective in p53-null pancreatic cancer cells resistant to wild-type TP53 gene replacement. Cancer Res. 2003; 63: 2737-2741.
21. Glinsky GV, Glinsky VV, Ivanova AB, Hueser CJ. Apoptosis and metastasis: increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms. Cancer Lett. 1997; 115: 185-193.
22. Fujimoto A, Takeuchi H, Taback B, et al. Allelic Imbalance of 12q22-23 associated with Apaf-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res. 2004; 64: 2245-2250.
23. Dai DL, Martinka M, Bush JA, Li G. Reduced Apaf-1 expression in human cutaneous melanomas. Br. J. Cancer 2004; 91: 1089-1095.
24. Baldi A, Santini D, Russo P, et al. Analysis of APAF-1 expression in human cutaneous melanoma progression. Experiment. Dermatol. 2004; 13: 93-97.
25. Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001; 409: 207-211.
26. Sun XF. p73 overexpression is a prognostic factor in patients with colorectal adenocarcinoma. Clin. Cancer Res. 2002; 8: 165-170.
27. Tannapfel A, Wasner M, Krause K, et al. Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. J. Natl. Cancer Inst. 1999; 91: 1154-1158.
28. Petrenko O, Zaika A, Moll UM. deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Mol. Cell Biol. 2003; 23: 5540-5555.
29. Kroiss MM, Bosserhoff AK, Vogt T, et al. Loss of expression or mutations in the p73 tumour suppressor gene are not involved in the pathogenesis of malignant melanomas. Melanoma Res. 1998; 8: 504-509.
30. Yamashita T, Tokino T, Tonoki H, et al. Induction of apoptosis in melanoma cell lines by p53 and its related proteins. J. Invest. Dermatol. 2001; 117: 914-919.
31. Sauter ER, Takemoto R, Litwin S, Herlyn M. p53 alone or in combination with antisense cyclin D1 induces apoptosis and reduces tumor size in human melanoma. Cancer Gene Ther. 2002; 9: 807-912.